News

Public · Published

Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

Enhertu has been approved in the European Union as a standalone adjuvant treatment for adults with resected HER2 positive breast cancer who still have invasive disease after neoadjuvant taxane-based and HER2 targeted therapy.

Published:

Updated:

What happened

Enhertu has been approved in the European Union as a standalone adjuvant treatment for adults with resected HER2 positive breast cancer who still have invasive disease after neoadjuvant taxane-based and HER2 targeted therapy.

Confirmed

Global impact / market context

Approval gives Daiichi Sankyo and AstraZeneca, which jointly develop and sell Enhertu, a new patient group in Europe. The trial showed a 53% lower risk of invasive disease returning or death versus T-DM1, which means fewer relapses may support adoption and revenue.

Analyst inference

The decision follows a positive opinion from the European Medicines Agency's human medicines committee and rests on the DESTINY-Breast05 phase 3 trial, presented in 2025 and published in The New England Journal of Medicine. That evidence base may shape how doctors and payers adopt the drug.

Analyst inference

What to watch

  1. Watch for how European doctors and hospitals put the approval into practice for adults with residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Confirmed
  2. Watch whether uptake lifts Enhertu revenue for Daiichi Sankyo and AstraZeneca, since both jointly develop and commercialize the drug and share its commercial results. Analyst inference
  3. Watch payers and health systems in Europe, because reimbursement decisions determine whether eligible patients can actually receive the treatment after surgery. Analyst inference

Evidence

  • Original source link unavailable